Commentary on: "Further studies are necessary in order to conclude a causal association between the consumption of monosodium L-glutamate (MSG) and the prevalence of the metabolic syndrome in the rural Thai population"
© Collison; licensee BioMed Central Ltd. 2013
Received: 5 January 2013
Accepted: 11 January 2013
Published: 22 January 2013
See related article: http://www.nutritionandmetabolism.com/content/10/1/14
I read with considerable interest the epidemiological study by Insawang et al., which demonstrates an association between monosodium glutamate (MSG) intake and the prevalence of the Metabolic Syndrome in a rural Thai population . It is important to point out that Insawang et al. did not claim that MSG causes the Metabolic Syndrome, they did however concluded that “elevated dietary MSG consumption is significantly associated with having the Metabolic Syndrome and being overweight in a Thai rural population”.
Hypertension, defined as elevated blood pressure defined as = 130/85 mmHg.
Abdominal obesity defined as waist circumference = 102 cm or 40 inches (male), or = 88 cm or 36 inches (female).
Hyperglycemia, defined as elevated Fasting plasma glucose = 110 mg/dl.
Dyslipidemia, defined as elevated triglycerides = 150mg/dL.
Dyslipidemia, defined as presence of high-density lipoprotein cholesterol (HDL-C) = 40 mg/dL (male), or = 50 mg/dL (female).
Importantly, elevated body weight is not one of the criteria for the presence of the Metabolic Syndrome; and indeed, animal model systems indicate that MSG-obese rodents exhibit either lower body weights [7–10], or similar body weights compared to control animals [11, 12], depending on the species and experimental conditions. However, impaired cardiovascular autonomic function, elevated arterial pressure, insulin resistance and dyslipidemia have all been documented in rodents exposed to MSG during the neonatal period at a time when the blood brain barrier is immature and vulnerable to excitotoxicity [13, 14]. Moreover, neonatal exposure to non-physiological levels of MSG is a proven experimental methodology for inducing Metabolic Syndrome in rodents [15–18]; and sometimes referred to as “hypothalamic obesity” [19, 20] due to the fact that high levels of glutamate may damage the hypothalamus and other areas of the brain which are rich in glutamate receptors [11, 12]. Interestingly, increased hypothalamic inflammatory signaling and neuronal injury can also be induced in rodents consuming high fat diets [21–24]; and recent data also provides evidence of hypothalamic low-grade inflammation and gliosis in obese humans [24, 25], which may impair the regulation of food intake and energy expenditure.
 The authors of the epidemiological study associating MSG consumption with the prevalence of Metabolic Syndrome were under no obligation to provide a causal relationship between the two.  Under experimental conditions in rodents, non-physiological levels of MSG, or high levels of dietary fat may promote damage to the hypothalamus and other areas of the brain regulating energy expenditure.  In humans, obesity may be associated with hypothalamic damage. The commentary by Rogers has provided several interesting points of discussion.
- Insawang T, Selmi C, Cha'on U, Pethlert S, Yongvanit P, Areejitranusorn P, Boonsiri P, Khampitak T, Tangrassameeprasert R, Pinitsoontorn C, Prasongwattana V, Gershwin ME, Hammock BD: Monosodium glutamate (MSG) intake is associated with the prevalence of metabolic syndrome in a rural Thai population. Nutr Metab (Lond). 2012, 9: 50-10.1186/1743-7075-9-50.View Article
- Rogers MD: Further studies are necessary to conclude a causal association between the consumption of monosodium L-glutamate (MSG) and the prevalence of metabolic syndrome in the rural Thai population. Nutr Metab (Lond). 2013, in press
- Shi Z, Luscombe-Marsh ND, Wittert GA, Yuan B, Dai Y, Pan X, Taylor AW: Monosodium glutamate is not associated with obesity or a greater prevalence of weight gain over 5 years: findings from the Jiangsu Nutrition Study of Chinese adults. Br J Nutr. 2010, 104: 457-463. 10.1017/S0007114510000760.View Article
- Samuels A: Monosodium glutamate is not associated with obesity or a greater prevalence of weight gain over 5 years: findings from the Jiangsu Nutrition Study of Chinese adults–comments by Samuels. Br J Nutr. 2010, 104 (11): 1729-10.1017/S0007114510002758.View Article
- Shi Z, Yuan B, Taylor AW, Dai Y, Pan X, Gill TK, Wittert GA: Monosodium glutamate is related to a higher increase in blood pressure over 5 years: findings from the Jiangsu Nutrition Study of Chinese adults. J Hypertens. 2011, 29: 846-853. 10.1097/HJH.0b013e328344da8e.View Article
- The National Cholesterol Education Program Adult Treatment Panel III (NCEP). http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf,
- Kondoh T, Torii K: MSG intake suppresses weight gain, fat deposition, and plasma leptin levels in male Sprague–Dawley rats. Physiol Behav. 2008, 95 (1–2): 135-144.View Article
- Kim YW, Choi DW, Park YH, Huh JY, Won KC, Choi KH, Park SY, Kim JY, Lee SK: Leptin-like effects of MTII are augmented in MSG-obese rats. Regul Pep. 2005, 127 (1–3): 63-70.View Article
- Dolnikoff M, Martín-Hidalgo A, Machado UF, Lima FB, Herrera E: Decreased lipolysis and enhanced glycerol and glucose utilization by adipose tissue prior to development of obesity in monosodium glutamate (MSG) treated-rats. Int J Obes Relat Metab Disord. 2001, 25 (3): 426-433. 10.1038/sj.ijo.0801517.View Article
- Magariños AM, Estivariz F, Morado MI, De Nicola AF: Regulation of the central nervous system-pituitary-adrenal axis in rats after neonatal treatment with monosodium glutamate. Neuroendocrinology. 1988, 48 (2): 105-111. 10.1159/000124997.View Article
- Bunyan J, Murrell EA, Shah PP: The induction of obesity in rodents by means of monosodium glutamate. Br J Nutr. 1976, 35 (1): 25-39. 10.1079/BJN19760005.View Article
- Matysková R, Maletínská L, Maixnerová J, Pirník Z, Kiss A, Zelezná B: Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice. Physiol Res. 2008, 57 (5): 727-734.
- Konrad SP, Farah V, Rodrigues B, Wichi RB, Machado UF, Lopes HF, D'Agord Schaan B, De Angelis K, Irigoyen MC: Monosodium glutamate neonatal treatment induces cardiovascular autonomic function changes in rodents. Clinics (Sao Paulo). 2012, 67 (10): 1209-1214. 10.6061/clinics/2012(10)14.View Article
- Seiva FR, Chuffa LG, Braga CP, Amorim JP, Fernandes AA: Quercetin ameliorates glucose and lipid metabolism and improves antioxidant status in postnatally monosodium glutamate-induced metabolic alterations. Food Chem Toxicol. 2012, 50 (10): 3556-3561. 10.1016/j.fct.2012.07.009.View Article
- Chen W, Wang LL, Liu HY, Long L, Li S: Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice. Basic Clin Pharmacol Toxicol. 2008, 103 (3): 240-246. 10.1111/j.1742-7843.2008.00268.x.View Article
- Diniz YS, Faine LA, Galhardi CM, Rodrigues HG, Ebaid GX, Burneiko RC, Cicogna AC, Novelli EL: Monosodium glutamate in standard and high-fiber diets: metabolic syndrome and oxidative stress in rats. Nutrition. 2005, 21 (6): 749-755. 10.1016/j.nut.2004.10.013.View Article
- Fujimoto M, Tsuneyama K, Fujimoto T, Selmi C, Gershwin ME, Shimada Y: Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis. 2012, 44 (9): 767-774. 10.1016/j.dld.2012.02.002.View Article
- Sasaki Y, Shimada T, Iizuka S, Suzuki W, Makihara H, Teraoka R, Tsuneyama K, Hokao R, Aburada M: Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. Eur J Pharmacol. 2011, 662 (1–3): 1-8.View Article
- Scomparin DX, Grassiolli S, Gomes RM, Torrezan R, de Oliveira JC, Gravena C, Pêra CC, Mathias PC: Low-Intensity swimming training after weaning improves glucose and lipid homeostasis in MSG hypothalamic obese mice. Endocr Res. 2011, 36 (2): 83-90. 10.3109/07435800.2010.534750.View Article
- Perello M, Castrogiovanni D, Giovambattista A, Gaillard RC, Spinedi E: Prolonged but not short negative energy condition restored corticoadrenal leptin sensitivity in the hypothalamic obese rat. Neuroendocrinology. 2009, 89 (3): 276-287. 10.1159/000193061.View Article
- De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad MJ, Velloso LA: Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology. 2005, 146 (10): 4192-4199. 10.1210/en.2004-1520.View Article
- Milanski M, Degasperi G, Coope A, Morari J, Denis R, Cintra DE, Tsukumo DM, Anhe G, Amaral ME, Takahashi HK, Curi R, Oliveira HC, Carvalheira JB, Bordin S, Saad MJ, Velloso LA: Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci. 2009, 29 (2): 359-370.View Article
- Posey KA, Clegg DJ, Printz RL, Byun J, Morton GJ, Vivekanandan-Giri A, Pennathur S, Baskin DG, Heinecke JW, Woods SC, Schwartz MW, Niswender KD: Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab. 2009, 296 (5): E1003-E1012. 10.1152/ajpendo.90377.2008.View Article
- Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, Zhao X, Sarruf DA, Izgur V, Maravilla KR, Nguyen HT, Fischer JD, Matsen ME, Wisse BE, Morton GJ, Horvath TL, Baskin DG, Tschöp MH, Schwartz MW: Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012, 122 (1): 153-162. 10.1172/JCI59660.View Article
- Cazettes F, Cohen JI, Yau PL, Talbot H, Convit A: Obesity-mediated inflammation may damage the brain circuit that regulates food intake. Brain Res. 2011, 1373: 101-109.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.